E-Z-Em gains distribution rights for Gadolite
Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY. E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures.
Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY.
E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures. As part of the agreement,the companies will collaborate on additional oral agents basedon Gadolite. Financial terms were not disclosed.
The agent has shown promise for abdominal and pelvic imaging,according to the company. Phase III trials were completed in thefirst quarter of 1995. Pharmacyclics expects to file a new drugapplication with the Food and Drug Administration by year-end.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
